Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 3 (endothelial cell) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0091 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.2407 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.2407 | 0.2407 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 420 nM | Inhibition of human iNOS expressed in human DLD1 cells after 1 hr | ChEMBL. | 18024030 |
IC50 (binding) | = 420 nM | Inhibition of human iNOS expressed in human DLD1 cells after 1 hr | ChEMBL. | 18024030 |
IC50 (binding) | = 590 nM | Inhibition of human nNOS expressed in insect SF9 cells after 1 hr | ChEMBL. | 18024030 |
IC50 (binding) | = 590 nM | Inhibition of human nNOS expressed in insect SF9 cells after 1 hr | ChEMBL. | 18024030 |
IC50 (binding) | = 820 nM | Inhibition of human eNOS expressed in insect SF9 cells after 1 hr | ChEMBL. | 18024030 |
IC50 (binding) | = 820 nM | Inhibition of human eNOS expressed in insect SF9 cells after 1 hr | ChEMBL. | 18024030 |
Inhibition (binding) | = 51 % | Inhibition of cytokine-induced iNOS activity in human DLD1 cells at 10 uM after 24 hrs | ChEMBL. | 18024030 |
Inhibition (binding) | = 51 % | Inhibition of cytokine-induced iNOS activity in human DLD1 cells at 10 uM after 24 hrs | ChEMBL. | 18024030 |
Ratio IC50 (binding) | = 1 | Selectivity for human nNOS to human iNOS | ChEMBL. | 18024030 |
Ratio IC50 (binding) | = 2 | Selectivity for human eNOS to human iNOS | ChEMBL. | 18024030 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.